Researchers from POSTECH and NeoImmuneTech, in collaboration with Kangwon National University, have discovered a way to enhance the effectiveness of bispecific antibody therapies in treating solid tumors. Bispecific antibodies can bind to two different antigens, engaging T cells to attack tumors. The team utilized a protein called rhIL-7-hyFc to increase bystander T cells in solid tumors, which, when activated by bispecific antibodies, can destroy tumor cells. This breakthrough addresses the limitations of bispecific antibodies in treating solid tumors, offering a potential solution to improve antitumor immunotherapy. The findings were published in “Cell Reports Medicine”, with hopes for validation through future clinical trials.
Source link
New method enhances the efficacy of bispecific antibody therapies in treating solid tumors
